Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling

Drug Metabolism and Disposition

Volumn 43, Issue 3, 2015, Pages 325-334

  Posada, Maria M ^a   Bacon, James A ^a   Schneck, Karen B ^a   Tirona, Rommel G ^b   Kim, Richard B ^b   Higgins, J William ^a   Pak, Y Anne ^a   Hall, Stephen D ^a   Hillgren, Kathleen M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; NAPROXEN; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; PEMETREXED; CARRIER PROTEIN; GLUTAMIC ACID DERIVATIVE; GUANINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DRUG INTERACTION INDEX; DRUG INHIBITION; DRUG POTENCY; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; HEK PEAK CELL LINE; HUMAN; IC50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; MALE; MATHEMATICAL ANALYSIS; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PROTEIN EXPRESSION; RISK ASSESSMENT; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; DRUG INTERACTION; HELA CELL LINE; KIDNEY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG INTERACTIONS; FEMALE; GLUTAMATES; GUANINE; HELA CELLS; HUMANS; IBUPROFEN; KIDNEY; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 84921405657     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059618     Document Type: Article

References (52)

1. Aarons L, Grennan DM, Rajapakse C, Brinkley J, Siddiqui M, Taylor L, and Higham C (1983a) Anti-inflammatory (ibuprofen) drug therapy in rheumatoid arthritis-rate of response and lack of time dependency of plasma pharmacokinetics. Br J Clin Pharmacol 15:387-388.
2. Aarons L, Grennan DM, and Siddiqui M (1983b) The binding of ibuprofen to plasma proteins. Eur J Clin Pharmacol 25:815-818.
3. Albert KS, Gillespie WR, Wagner JG, Pau A, and Lockwood GF (1984) Effects of age on the clinical pharmacokinetics of ibuprofen. Am J Med 77 (1A):47-50.
4. Avdeef A, Berger CM, and Brownell C (2000) pH-metric solubility. 2: Correlation between the acid-base titration and the saturation shake-flask solubility-pH methods. Pharm Res 17:85-89.
5. Avdeef A, Box KJ, Comer JE, Gilges M, Hadley M, Hibbert C, Patterson W, and Tam KY (1999) PH-metric log P 11. pKa determination of water-insoluble drugs in organic solvent-water mixtures. J Pharm Biomed Anal 20:631-641.
6. Bajetta E, Celio L, Buzzoni R, Ferrari L, Marchiano A, Martinetti A, Longarini R, Becerra C, Ilardi C, and JohnW (2003) Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 14:1543-1548.
7. Bakhiya A, Bahn A, Burckhardt G, and Wolff N (2003) Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 13:249-256.
8. Bouzom F, Ball K, Perdaems N, and Walther B (2012) Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm Drug Dispos 33:55-71.
9. Burckhardt G (2012) Drug transport by organic anion transporters (OATs). Pharmacol Ther 136: 106-130.
10. Cassano WF (1989) Serious methotrexate toxicity caused by interaction with ibuprofen. Am J Pediatr Hematol Oncol 11:481-482.
11. Chen Y, Jin JY, Mukadam S, Malhi V, and Kenny JR (2012) Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm Drug Dispos 33:85-98.
12. Cockcroft DW and Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
13. Croset A, Delafosse L, Gaudry JP, Arod C, Glez L, Losberger C, Begue D, Krstanovic A, Robert F, and Vilbois F, et al. (2012) Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. J Biotechnol 161:336-348.
14. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and Pglycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
15. Davies NM (1998) Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 34:101-154.
16. Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M, Chan W, Huang CC, Johns SJ, and Kawamoto M, et al. (2006) The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol 290: F905-F912.
17. Frenia ML and Long KS (1992) Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 26:234-237.
18. Godinot N, Iversen PW, Tabas L, Xia X, Williams DC, Dantzig AH, and Perry WL, 3rd (2003) Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ ABCC1) from the cynomolgus monkey. Mol Cancer Ther 2:307-316.
19. Goodman LS and Gilman A (1941) The Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology and Therapeutics for Physicians and Medical Students, Macmillan, New York.
20. Grennan DM, Aarons L, Siddiqui M, Richards M, Thompson R, and Higham C (1983) Doseresponse study with ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. Br J Clin Pharmacol 15:311-316.
21. Hagos Y, Bahn A, Vormfelde SV, Brockmöller J, and Burckhardt G (2007a) Torasemide transport by organic anion transporters contributes to hyperuricemia. J Am Soc Nephrol 18: 3101-3109.
22. Hagos Y, Stein D, Ugele B, Burckhardt G, and Bahn A (2007b) Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 18:430-439.
23. Hsu V, de L T Vieira M, Zhao P, Zhang L, Zheng JH, Nordmark A, Berglund EG, Giacomini KM, and Huang SM (2014) Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin Pharmacokinet 53:283-293.
24. Jackson VN and Halestrap AP (1996) The kinetics, substrate, and inhibitor specificity of the monocarboxylate (lactate) transporter of rat liver cells determined using the fluorescent intracellular pH indicator, 2′,7′-bis(carboxyethyl)-5(6)-carboxyfluorescein. J Biol Chem 271: 861-868.
25. Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N, Piyachaturawat P, and Endou H (2002) Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 303: 534-539.
26. Kurata T, Iwamoto T, Kawahara Y, and Okuda M (2014) Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3. Drug Metab Pharmacokinet 29:148-153.
27. Latz JE, Chaudhary A, Ghosh A, and Johnson RD (2006) Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 57: 401-411.
28. Lockwood GF, Albert KS, Gillespie WR, Bole GG, Harkcom TM, Szpunar GJ, and Wagner JG (1983a) Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships. Clin Pharmacol Ther 34:97-103.
29. Lockwood GF, Albert KS, Szpunar GJ, and Wagner JG (1983b) Pharmacokinetics of ibuprofen in man-III: Plasma protein binding. J Pharmacokinet Biopharm 11:469-482.
30. Mills RF, Adams SS, Cliffe EE, Dickinson W, and Nicholson JS (1973) The metabolism of ibuprofen. Xenobiotica 3:589-598.
31. Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, and Chaudhuri T, et al. (2006) Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24:552-562.
32. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, and Inui K (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866-874.
33. Nakagawa K, Kudoh S, Matsui K, Negoro S, Yamamoto N, Latz JE, Adachi S, and Fukuoka M (2006) A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 95:677-682.
34. Nozaki Y, Kusuhara H, Endou H, and Sugiyama Y (2004) Quantitative evaluation of the drugdrug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther 309:226-234.
35. Pratt SE, Emerick RM, Horwit L, Gallery M, Lesoon A, Jink S, Chen VJ, and Dantzig AH (2002) Multidrug resistance proteins (MRP) 2 and 5 transport and confer resistance to Alimta (Abstract). Proc Am Assoc Cancer Res 43:782.
36. Ragni MV, Miller BJ, Whalen R, and Ptachcinski R (1992) Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. Am J Hematol 40:176-182.
37. Rinaldi DA (1999) Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin Oncol 26(2, Suppl 6)82-88.
38. Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, and Langley C, et al. (1999) A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372-380.
39. Rodgers T, Leahy D, and Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1276.
40. Rodgers T and Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
41. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, and Symanowski JT, et al. (2003) Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21:1556-1561.
42. Shaw LR, Irwin WJ, Grattan TJ, and Conway BR (2005) The effect of selected water-soluble excipients on the dissolution of paracetamol and Ibuprofen. Drug Dev Ind Pharm 31:515-525.
43. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, and Patel VF, et al. (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123.
44. Straumann N, Wind A, Leuenberger T, and Wallimann T (2006) Effects of N-linked glycosylation on the creatine transporter. Biochem J 393:459-469.
45. Sweeney CJ, Takimoto CH, Latz JE, Baker SD, Murry DJ, Krull JH, Fife K, Battiato L, Cleverly A, and Chaudhary AK, et al. (2006) Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. Clin Cancer Res 12:536-542.
46. Sweet DH, Chan LM, Walden R, Yang XP, Miller DS, and Pritchard JB (2003) Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am J Physiol Renal Physiol 284:F763-F769.
47. Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L, Beeram M, Forouzesh B, de Bono J, Tolcher AW, Patnaik A, and Monroe P, et al. (2007) Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 13:2675-2683.
48. Thyss A, Milano G, Kubar J, Namer M, and Schneider M (1986) Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1: 256-258.
49. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, and Brater DC (1992) The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 42:121-125.
50. Tsamandouras N, Rostami-Hodjegan A, and Aarons L (2013) Combining the "bottom-up" and "top-down" approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol DOI: 10.1111/bcp.12234 [published ahead of print].
51. Wagner JG, Albert KS, Szpunar GJ, and Lockwood GF (1984) Pharmacokinetics of ibuprofen in man IV: absorption and disposition. J Pharmacokinet Biopharm 12:381-399.
52. Yee S (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 14:763-766.